Print
ProHeart 12 Provides 12 Months of Continuous Protection
ProHeart 12 Showed Complete Efficacy Against Dirofilaria immitis in 3 Well-Controlled Studies
One injection provided 12 MONTHS OF HEARTWORM* DISEASE PROTECTION and was 100% effective
ProHeart 12 was tested in a field study across 19 clinics, including 4 in the Lower Mississippi River Valley (LMRV)† region where resistant strains of heartworm disease have been identified, and was 100% effective.‡1
In 7 laboratory studies, ProHeart 12 also demonstrated ≥90% efficacy against hookworms§
The ProHeart 12 Mode of Action Works All Year Long for Dogs
And works continuously vs short-term monthly chewables
ProHeart 12 uses microspheres to prolong the effects of the active ingredient, moxidectin.
As the microspheres dissolve, moxidectin is absorbed and then redistributed from plasma to adipose tissue.
The adipose tissue acts like a reservoir, allowing for up to one year of protection‖ against heartworm disease and is the only year-long injectable continuous preventative, compared with the action of monthly macrocyclic lactones.
Get Certified Today
If you’re already certified to administer ProHeart 6® (moxidectin), you do not need to recertify for ProHeart 12.
Certify NowOrder ProHeart 12
Already certified? Sign in or register today to order ProHeart 12. It's an easy process that can be done directly online.
Order Online
Help Your Clients Understand the Importance of Heartworm Protection
Access these valuable tools and resources for your practice.
View Resources*Dirofilaria immitis.
†The LMRV has some of the highest incidence rates of heartworm in the country, as measured by the American Heartworm Society.
‡As measured on Days 365, 480, and 605.1
§Ancylostoma caninum and Uncinaria stenocephala.
‖One year for ProHeart 12; 6 months for ProHeart 6.
IMPORTANT SAFETY INFORMATION: Use PROHEART 12 in dogs 12 months of age or older. Do not administer to dogs that are sick, debilitated, underweight, have a history of weight loss, or to those previously found to be hypersensitive to the drug. Hypersensitivity reactions may occur in some dogs when PROHEART 12 is administered alone or with vaccines. Anaphylactic and anaphylactoid reactions can result in death and should be treated immediately with the same measures used to treat hypersensitivity reactions to vaccines and other injectable products. The most common reported side effects in clinical trials were vomiting, lethargy, diarrhea, and anorexia. People should avoid inhalation, contact with eyes, or accidental self-injection. Certification is required before veterinarians and staff administer PROHEART 12. See full Prescribing Information.
Reference: 1. Study A161C-US-13-330. Data on File. Zoetis Inc.
The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.
All trademarks are the property of their respective owners.
©2019 Zoetis Services LLC. All rights reserved. PHT-00016
CONTACT US
United States 
For animals. For health. For you.
This site is intended for U.S. Animal Healthcare Professionals. The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.
All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. ©2022 Zoetis Services LLC. All rights reserved.
